Business
Citius Pharmaceuticals Expands Scientific Advisory Board with Addition of Dr. John Laffey, Expert in Stem Cell and Gene Therapies for ARDS
- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of Citius'
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of Citius' novel induced mesenchymal stem cell (i-MSC) program -\n\n\n\n CRANFORD, N.J., June 15, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), effective immediately.\n\n \n \n \n \n \n \n\n \nDr. Laffey joins noted colleagues, Dr. Michael A. Matthay, Dr. Lorraine B. Ware, Dr. Mitchell M. Levy, and Dr. Perenlei Enkhbaatar on the ARDS SAB. Each member of the board is a recognized key opinion leader (KOL) with extensive clinical trial expertise in the treatment of acute lung disorders. \n\"We are delighted to welcome John to our distinguished ARDS Scientific Advisory Board and look forward to leveraging his deep insights and decades of hands-on experience with ARDS to advance our proprietary i-MSC program,\" stated Myron Holubiak, President and Chief Executive Officer of Citius. \n\"Dr. Laffey is a highly accomplished and recognized expert in acute lung disorders. His cutting-edge research into the use of gene and stem cell-based therapies to treat ARDS will provide Citius with an important perspective as we explore the potential of this exciting new therapeutic area. Development of our i-MSC master cell bank for future trials is underway, and I am confident that John's expertise and guidance will complement our SAB and help direct our clinical efforts,\" concluded Mr. Holubiak. \nDr. John Laffey is Professor of Anesthesia and Intensive Care Medicine at the School of Medicine of the National University of Ireland (NUI Galway), and a Consultant in Anesthesia and Intensive Care Medicine at Galway University Hospitals. He is Director of Clinical Research at Saolta Hospital Group and NUI Galway. Dr. Laffey's primary focus is on the investigation of therapeutic strategies for ARD...